Osteosarcoma of rib treated with regorafenib: a case report

Year 2021, Volume: 3 Issue: Supplement 1, 62 - 64, 07.03.2021

Orkun Sakar , Cemre Uçaryılmaz , Ahmet Bilgehan Şahin , Türkkan Evrensel , Cengiz Gebitekin

https://doi.org/10.46310/tjim.875951

https://izlik.org/JA97FZ54EM

Abstract

Osteosarcoma is a common primary malignant bone tumor in young adults presenting with back and chest pain complaints. Here, we presented a rare case of osteosarcoma.

Keywords

oncology , osteosarcoma of rib , regorafenib

Supporting Institution

Bursa Uludag University Faculty of Medicine

Thanks

We thank our patient for allowing her data to be used in this scientific study

References

• Mirabello L, Troisi R J, Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43. doi: 10.1002/cncr.24121.
• Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol . 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.
• Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3.